- President Donald Trump expects a coronavirus vaccine to arrive in the fall. Politico reported.
- This schedule could even prove to be faster than the federal government's ambitious drive to deliver vaccines to Americans by January 2021.
- Many experts have warned that a vaccine could reach humans at the earliest in 2021.
- Vaccine production was unusually fast, and several companies ramped up production and pushed trials.
- You can find more stories on the Business Insider homepage.
President Donald Trump expects a coronavirus vaccine to arrive in the fall, apparently based on a schedule that is much faster than many experts think possible.
Trump has told both his advisors and allies that he is expecting this schedule for the arrival of the vaccine. According to a report by Nancy Cook and Gabby Orr from Politico.
Vaccine manufacturers around the world are trying to develop a vaccine against COVID-19 at an unprecedented rate.
They hope that life in large parts of the world can be normalized once it is administered far enough.
It is not clear which phase of Trump's vaccine production means "arrival", but autumn 2020 is optimistic for even more preparatory steps on the way to a working vaccine.
Almost no one expects a vaccine to be in circulation in the fall to protect normal people.
When Trump refers to the vaccine being released to the public, he's ahead of his own government's $ 10 billion Operation Warp Speed project.
This is expected to deliver 300 million doses of vaccine by January 2021.
Dr. Anthony Fauci, the U.S. government's leading infectious disease expert, said in May it was a "bridge too far" to think a vaccine will be ready before college starts in the fall.
In a later timeline in front of the congress, Fauci said a vaccine could be given to the American public by the end of this year or early 2021.
Other experts are much more pessimistic.
Other experts have said that even the 2021 schedule is ambitious.
Dr. Paul Offit, who helped invent the rotavirus vaccine, said CNN in April that this timeline was "ridiculously optimistic".
And then Peter Hotez, the dean of the National School of Tropical Medicine at Baylor University said National Geographic that it was "absolutely unprecedented".
David Ridley, health economist at Duke University, said The Associated Press in June that even if the cans were ready in the United States by the end of 2020, "only a few high-risk individuals, such as key workers, are at the forefront of a very long line".
"Will you and I be vaccinated this year?" He asked. "Under no circumstance."
To be available to the public in countries around the world, vaccines must go through several phases, including development, clinical trials, regulatory approval, production, and distribution.
Experts warn that even the comparatively simple steps could pose major obstacles. The United States spends hundreds of millions of dollars to address a shortage of glass bottles that could affect the supply chain, for example.
Manufacturers are sticking to quick schedules: American biotechnology Moderna plans to give a small dose to 30,000 in a phase three study in July, while Sanofi in France does Accelerate the development of a vaccine that could receive regulatory approval in the first half of next year.
Manufacturers like Moderna are too Production increased to produce millions of vaccine doses to prepare them for distribution, it is hoped that they will be approved.
But it is also possible that an effective vaccine will never come: there is still no vaccine against viruses that have long plagued people, such as HIV and hepatitis C.
And, as Vox reportedIt is not yet clear how long immunity to a vaccine would last.